First produced only in the past decade, human induced pluripotent stem cells (iPSCs) are capable of developing into many or even all human cell types. In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases—and eventually in treating them.
"The technology for generating these cells has been moving very quickly," said hematologist Mitchell J. Weiss, M.D., Ph.D., corresponding author of two recent studies led by The Children's Hospital of Philadelphia (CHOP). "These investigations can allow us to better understand at a molecular level how blood cells go wrong in individual patients—and to test and generate innovative treatments for the patients' diseases."
Weiss, with Monica Bessler, M.D., Philip Mason, Ph.D., and Deborah L. French, Ph.D., all of CHOP, led a study on iPSCs and Diamond Blackfan anemia (DBA) published online June 6 in Blood. Another study by Weiss, French and colleagues in the same journal on April 25 focused on iPSCs in juvenile myelomonocytic leukemia (JMML).
In DBA, a mutation prevents a patient's bone marrow from producing normal quantities of red blood cells, resulting in severe, sometimes life-threatening anemia. This basic fact makes it difficult for researchers to discern the underlying mechanism of the disease: "It's very difficult to figure out what's wrong, because the bone marrow is nearly empty of these cells," said Bessler, the director of CHOP's Pediatric and Adult Comprehensive Bone Marrow Failure Center.
The study team removed fibroblasts (skin cells) from DBA patients, and in cell cultures, using proteins called transcription factors, reprogrammed the cells into iPSCs. As those iPSCs were stimulated to form blood tissues, like the patient's original mutated cells, they were deficient in producing red blood cells.
However, when the researchers corrected the genetic defect that causes DBA, the iPSCs developed into red blood cells in normal quantities. "This showed that in principle, it's possible to repair a patient's defective cells," said Weiss.
Weiss cautioned that this proof-of-principle finding is an early step, with many further studies to be done to verify if this approach will be safe and effective in clinical use.
However, he added, the patient-derived iPSCs are highly useful as a model cell system for investigating blood disorders. For instance, DBA is often puzzling, because two family members may have the same mutation, but only one may be affected by the disease. Because each set of iPSCs is specific to the individual from whom they are derived, researchers can compare the sets to identify molecular differences, such as a modifier gene active in one person but not the other.
Furthermore, the cells offer a renewable, long-lasting model system for testing drug candidates or gene modifications that may offer new treatments, personalized to individual patients.
The second study in Blood provides a concrete example of using iPSCs for drug testing, specifically for the often-aggressive childhood leukemia, JMML. First the study team generated iPSCs from two children with JMML, and then manipulated the iPSCs in cell cultures to produce myeloid cells that multiplied uncontrollably, much as the original JMML cells do.
They then tested the cells with two drugs, each able to inhibit a separate protein known to be highly active in JMML. One drug, an inhibitor of the MEK kinase, reduced the proliferation of cancerous cells in culture. "This provides a rationale for a potential targeted therapy for this specific subtype of JMML," said Weiss.
A stem cell core facility at CHOP, directed by study co-author Deborah French under the auspices of the hospital's Center for Cellular and Molecular Therapeutics, generated the iPSCs lines used in these studies. The facility's goal is to develop and maintain standardized iPSCs lines specific to a variety of rare inherited diseases—not only DBA and JMML, but also dyskeratosis congenita, congenital dyserythropoietic anemia, thrombocytopenia absent radii (TAR), Glanzmann's thrombasthenia and Hermansky- Pudlak syndrome.
A longer-term goal, added Weiss, is for the iPSC lines to provide the raw materials for eventual cell therapies that could be applied to specific genetic disorders. "The more we learn about the molecular details of how these diseases develop, the closer we get to designing precisely targeted tools to benefit patients."
The National Institutes of Health (grants HL101606, DK090969) supported both studies. Also supporting the Diamond Blackfan anemia study were the U.S. Department of Defense (grant BM090168), and N.I.H. grants CA106995, CA105312, RR024134, and TR000003. Other funders of the JMML study were N.I.H. grants HL099656 and CA082103, the Cookies for Kids' Cancer Foundation, the Leukemia and Lymphoma Society and the Frank A. Campini Foundation. Weiss's research on stem cells is also supported by the Jane Fishman Grinberg Endowed Chair and Bessler receives support from the Buck Family Endowed Chair in Hematology.
"Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients," Blood, published online June 6, 2013. http://doi.org/10.1182/blood-2013-01-478321
"Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia," Blood, published online April 25, 2013. http://doi.org/10.1182/blood-2013-01-478412
About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program receives the highest amount of National Institutes of Health funding among all U.S. children's hospitals. In addition, its unique family-centered care and public service programs have brought the 527-bed hospital recognition as a leading advocate for children and adolescents.
John Ascenzi | EurekAlert!
Further reports about: > Blackfan > CHOP > DBA > Gates Foundation > Reprogramming > blood cell > blood disorders > blood flow > cell cultures > cell type > genetic disorder > health services > induced pluripotent stem > induced pluripotent stem cell > pluripotent stem > pluripotent stem cells > raw material > red blood cells > stem cells > transcription factor
Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz
Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
28.04.2017 | Event News
20.04.2017 | Event News
18.04.2017 | Event News
28.04.2017 | Medical Engineering
28.04.2017 | Earth Sciences
28.04.2017 | Life Sciences